ASX Announcements


 
25-Sep-2023    Mernova New Purchase Orders Update  
 
12-Sep-2023    Proposed issue of securities - ME1  
 
12-Sep-2023    Notice of General Meeting/Proxy Form  
 
11-Sep-2023    Mernova Maiden Alberta PO and Revenue Update  
 
5-Sep-2023    Proposed issue of securities - ME1  
 
4-Sep-2023    Cleansing Notice  
 
4-Sep-2023    Debt Restructure Update  
 
4-Sep-2023    Application for quotation of securities - ME1  
 
4-Sep-2023    ImpACTIVE Sponsorship Deal & Promising Regulatory Shifts  
 
31-Aug-2023    Half Year Results Commentary  
 
31-Aug-2023    Half Yearly Report and Accounts  
 
28-Aug-2023    Application for quotation of securities - ME1  
 
21-Aug-2023    Mernova Q3 Sales Update  
 
18-Aug-2023    Restricted Securities to be Released from Escrow  
 
14-Aug-2023    Cleansing Notice  
 
14-Aug-2023    Application for quotation of securities - ME1  
 
11-Aug-2023    Response to ASX Aware Query  
 
9-Aug-2023    Cleansing Notice  
 
8-Aug-2023    Application for quotation of securities - ME1  
 
8-Aug-2023    Application for quotation of securities - ME1  
 
8-Aug-2023    Proposed issue of securities - ME1  
 
8-Aug-2023    Proposed issue of securities - ME1  
 
8-Aug-2023    Proposed issue of securities - ME1  
 
8-Aug-2023    Capital Raising and Debt to Equity Conversions  
 
4-Aug-2023    Trading Halt  
 
2-Aug-2023    LOI for Sale of Sierra Sage and Halucenex to Panacea  
 
31-Jul-2023    Cancel - Proposed issue of securities - ME1  
 
31-Jul-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
26-Jul-2023    Mernova Makes Strong Progress on EU GMP Licence Process  
 
24-Jul-2023    Subsidiary HHI Delivers Strong Revenue & EBITDA in H1 2023  
 
21-Jul-2023    Notification of cessation of securities - ME1  
 
19-Jul-2023    Strong Start to Q3 CY2023 with $1.6m in New Revenue & POs  
 
13-Jul-2023    Record Revenue Quarter With Group Sales Up 105%  
 
10-Jul-2023    Mernova Delivers Record Half Yearly Revenues  
 
7-Jul-2023    Notification regarding unquoted securities - ME1  
 
7-Jul-2023    Application for quotation of securities - ME1  
 
6-Jul-2023    Change of Director's Interest Notice x2  
 
3-Jul-2023    Health House International Revenue Update  
 
30-Jun-2023    Appendix 3G  
 
30-Jun-2023    Appendix 2A  
 
26-Jun-2023    Appendix 2A  
 
26-Jun-2023    Appendix 3H  
 
21-Jun-2023    Appendix 2A  
 
21-Jun-2023    Change in substantial holding  
 
19-Jun-2023    Appendix 3B - Amendment  
 
19-Jun-2023    Appendix 3B  
 
15-Jun-2023    Appendix 3G  
 
15-Jun-2023    Appendix 2A  
 
15-Jun-2023    Disclosure Document  
 
14-Jun-2023    Appendix 3B  
 
14-Jun-2023    Appendix 2A  
 
14-Jun-2023    Debt Conversions and Extensions  
 
13-Jun-2023    Change of Company Name and ASX Code  
 
9-Jun-2023    Notification regarding unquoted securities - CPH  
 
9-Jun-2023    LOI to Import MDMA & Psilocybin Treatments to Australia  
 
9-Jun-2023    LOI to Import MDMA & Psilocybin Treatments to Australia  
 
8-Jun-2023    Application for quotation of securities - CPH  
 
6-Jun-2023    Notification of cessation of securities - CPH  
 
5-Jun-2023    Mernova Appoints CannDelta to Map EU GMP Export Process  
 
2-Jun-2023    Notification regarding unquoted securities - CPH  
 
2-Jun-2023    Cleansing Notice - Convertible Notes  
 
31-May-2023    Results of Meeting  
 
24-May-2023    SBC Facility - Second Purchase & Amortisation Payments  
 
24-May-2023    Application for quotation of securities - CPH  
 
24-May-2023    Proposed issue of securities - CPH  
 
24-May-2023    Application for quotation of securities - CPH  
 
24-May-2023    Cleansing Notice  
 
24-May-2023    Application for quotation of securities - CPH  
 
24-May-2023    Notification of cessation of securities - CPH  
 
24-May-2023    Application for quotation of securities - CPH  
 
24-May-2023    Application for quotation of securities - CPH  
 
22-May-2023    Mernova Q2 Sales Update  
 
19-May-2023    Proposed issue of securities - CPH  
 
19-May-2023    Proposed issue of securities - CPH  
 
19-May-2023    Proposed issue of securities - CPH  
 
19-May-2023    Capital Raising & Debt Repayment  
 
17-May-2023    Trading Halt  
 
16-May-2023    Notification regarding unquoted securities - CPH  
 
16-May-2023    Response to Financial Condition Query  
 
16-May-2023    Application for quotation of securities - CPH  
 
15-May-2023    Results of Meeting  
 
15-May-2023    Creso Pharma Expands Asia Market Footprint  
 
10-May-2023    Response to ASX Price Query  
 
10-May-2023    Sierra Sage Herbs LLC Update  
 
5-May-2023    Halucenex Phase II Clinical Trial Update  
 
2-May-2023    Application for quotation of securities - CPH  
 
1-May-2023    Notice of Annual General Meeting/Proxy Form  
 
1-May-2023    Mernova - Eighth Province Entry & $553k in New POs  
 
28-Apr-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
19-Apr-2023    Mernova - Q1 Cashflow Positive With Record Revenues  
 
14-Apr-2023    ASX Listing Rule 3.13.1 Notice Regarding AGM  
 
14-Apr-2023    Notice of General Meeting/Proxy Form  
 
6-Apr-2023    February Placement Update & Additional Information  
 
31-Mar-2023    Appendix 4G and Corporate Governance Statement  
 
31-Mar-2023    Annual Report to Shareholders  
 
29-Mar-2023    Notification of cessation of securities - CPH  
 
15-Mar-2023    Notification regarding unquoted securities - CPH  
 
13-Mar-2023    Resolution of Historical ASX Listing Rule Breach  
 
13-Mar-2023    Censure of Creso Pharma Limited  
 
13-Mar-2023    Cleansing Notice - Convertible Notes  
 
7-Mar-2023    Application for quotation of securities - CPH  
 
6-Mar-2023    Cancel - Proposed issue of securities - CPH  
 
6-Mar-2023    Proposed issue of securities - CPH  
 
6-Mar-2023    Proposed issue of securities - CPH  
 
6-Mar-2023    Proposed issue of securities - CPH  
 
6-Mar-2023    Proposed issue of securities - CPH  
 
6-Mar-2023    $2.5M Con Note Issue, Rollover & Extinguishment of Debt  
 
28-Feb-2023    Creso Reports Strong Financial Performance in FY22  
 
28-Feb-2023    Preliminary Final Report  
 
24-Feb-2023    Secondary Trading Notice  
 
24-Feb-2023    Application for quotation of securities - CPH  
 
17-Feb-2023    Proposed issue of securities - CPH  
 
17-Feb-2023    CPH Secures Firm Commitments to Raise $2m  
 
15-Feb-2023    Notification of cessation of securities - CPH  
 
15-Feb-2023    Trading Halt  
 
14-Feb-2023    Restricted Securities to be Released from Escrow  
 
9-Feb-2023    Creso reports strong progress across business units  
 
7-Feb-2023    Halucenex to pursue AUS entry after landmark TGA decision  
 
3-Feb-2023    Change of Director's Interest Notice x 2  
 
2-Feb-2023    Distribution Schedule  
 
2-Feb-2023    Top 20 securityholders  
 
2-Feb-2023    Appendix 2A  
 
31-Jan-2023    Application for quotation of securities - CPH  
 
31-Jan-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
27-Jan-2023    Notification regarding unquoted securities - CPH  
 
27-Jan-2023    Notification regarding unquoted securities - CPH  
 
27-Jan-2023    Proposed issue of securities - CPH  
 
27-Jan-2023    Disclosure Document  
 
27-Jan-2023    Proposed issue of securities - CPH  
 
27-Jan-2023    Proposed issue of securities - CPH  
 
27-Jan-2023    La Plata Debt Restructure & Abby and Finn LOI  
 
27-Jan-2023    Application for quotation of securities - CPH  
 
27-Jan-2023    Proposed issue of securities - CPH  
 
27-Jan-2023    Application for quotation of securities - CPH  
 
25-Jan-2023    Trading Halt  
 
25-Jan-2023    Pause in Trading  
 
24-Jan-2023    Mernova - New Province Entry & Largest Ever PO  
 
17-Jan-2023    Application for quotation of securities - CPH  
 
17-Jan-2023    Change of Director's Interest Notice x3  
 
12-Jan-2023    Notification regarding unquoted securities - CPH  
 
12-Jan-2023    Notification regarding unquoted securities - CPH  
 
12-Jan-2023    Notification of cessation of securities - CPH  
 
11-Jan-2023    Mernova wins seven new product listings in Nova Scotia  
 
10-Jan-2023    Secondary Trading Notice  
 
10-Jan-2023    Application for quotation of securities - CPH  
 
10-Jan-2023    Application for quotation of securities - CPH  
 
10-Jan-2023    Application for quotation of securities - CPH  
 
10-Jan-2023    Proposed issue of securities - CPH  
 
10-Jan-2023    ZLD: Receipt of Creso Shares and Settlement of HHI loan  
 
9-Jan-2023    Creso raises $500k in convertible notes  
 
9-Jan-2023    Application for quotation of securities - CPH  
 
9-Jan-2023    Notification regarding unquoted securities - CPH  
 
29-Dec-2022    Results of Meeting  
 
22-Dec-2022    Top 20 Holder Report  
 
20-Dec-2022    Notice of Expiry of Listed Options  
 
15-Dec-2022    Proposed issue of securities - CPH  
 
15-Dec-2022    Secured Convertible Notes Offer Update  
 
12-Dec-2022    Notification regarding unquoted securities - CPH  
 
8-Dec-2022    Extension of March Options Offer under Prospectus  
 
7-Dec-2022    Halucenex administers first dose  
 
5-Dec-2022    Response to ASX Query  
 
2-Dec-2022    Notification regarding unquoted securities - CPH  
 
2-Dec-2022    Application for quotation of securities - CPH  
 
2-Dec-2022    Application for quotation of securities - CPH  
 
2-Dec-2022    Initial Director's Interest Notice  
 
2-Dec-2022    Final Director's Interest Notice  
 
1-Dec-2022    Board Changes  
 
28-Nov-2022    Proposed issue of securities - CPH  
 
28-Nov-2022    Prospectus  
 
25-Nov-2022    Notice of General Meeting/Proxy Form  
 
23-Nov-2022    HHI Update & Product Registration Achieved in South Korea  
 
22-Nov-2022    Creso is no longer the subject of ASIC Investigation  
 
22-Nov-2022    Pause in trading  
 
21-Nov-2022    Proposed issue of securities - CPH  
 
21-Nov-2022    Proposed issue of securities - CPH  
 
21-Nov-2022    ZLD: Partial Receipt and variation of Health House loan  
 
18-Nov-2022    Mernova Update  
 
17-Nov-2022    Replacement of Chairman  
 
9-Nov-2022    Sierra Sage Herbs LLC Expands into Canada  
 
3-Nov-2022    Secondary Trading Notice  
 
3-Nov-2022    Application for quotation of securities - CPH  
 
3-Nov-2022    Mernova Secures Cannabis 2.0 Sales License  
 
1-Nov-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
1-Nov-2022    Proposed issue of securities - CPH  
 
1-Nov-2022    CPH Secures Commitments to Raise up to $7.6m  
 
28-Oct-2022    Trading Halt  
 
25-Oct-2022    Change of Director's Interest Notice  
 
25-Oct-2022    Notice of Breach of ASX Listing Rule 10.11  
 
19-Oct-2022    Application for quotation of securities - CPH  
 
17-Oct-2022    Final Director's Interest Notice  
 
14-Oct-2022    Initial Director's Interest Notice x2  
 
13-Oct-2022    Sierra Sage enters into agreement with accelerate360  
 
10-Oct-2022    Melodiol Global Health - Rebranding Strategy  
 
10-Oct-2022    Board Transition & Change of Company Name  
 
10-Oct-2022    Proposed issue of securities - CPH  
 
6-Oct-2022    Halucenex completes clinical trial patient recruitment  
 
4-Oct-2022    Mernova Update  
 
29-Sep-2022    Mernova Update  
 
20-Sep-2022    Notification of cessation of securities - CPH  
 
14-Sep-2022    Halucenex Update  
 
6-Sep-2022    Change of Director's Interest Notice  
 
6-Sep-2022    Becoming a substantial holder  
 
2-Sep-2022    Sierra Sage secures US$214,000 purchase order from Walmart  
 
31-Aug-2022    Half Yearly Report and Accounts  
 
31-Aug-2022    Secondary Trading Notice  
 
29-Aug-2022    Notification regarding unquoted securities - CPH  
 
29-Aug-2022    Application for quotation of securities - CPH  
 
29-Aug-2022    Creso Pharma completes Sierra Sage Herbs LLC Acquisition  
 
29-Aug-2022    Application for quotation of securities - CPH  
 
22-Aug-2022    Halucenex Update  
 
15-Aug-2022    Secondary Trading Notice  
 
15-Aug-2022    Application for quotation of securities - CPH  
 
15-Aug-2022    Proposed issue of securities - CPH  
 
15-Aug-2022    impACTIVE appoints New Brand Ambassador, Kolby Tullier  
 
9-Aug-2022    Results of Meeting  
 
8-Aug-2022    Proposed issue of securities - CPH  
 
8-Aug-2022    Application for quotation of securities - CPH  
 
8-Aug-2022    Mernova Update  
 
4-Aug-2022    Proposed issue of securities - CPH  
 
4-Aug-2022    Reinstatement to Official Quotation  
 
4-Aug-2022    Capital Raising & Q2 22 Quarterly Activities Report Updates  
 
2-Aug-2022    Extension to Voluntary Suspension  
 
1-Aug-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
29-Jul-2022    HHI: Creso makes non-binding ind.proposal to acquire HHI  
 
29-Jul-2022    Execution of non-binding term sheet to acquire Health House  
 
29-Jul-2022    Suspension from Quotation  
 
28-Jul-2022    Change of Director's Interest Notice  
 
28-Jul-2022    Notification of cessation of securities - CPH  
 
27-Jul-2022    Trading Halt  
 
25-Jul-2022    SSH secures Private Label Manufacturing Agreement  
 
21-Jul-2022    Mernova Update  
 
18-Jul-2022    Halucenex Update  
 
14-Jul-2022    Proposed issue of securities - CPH  
 
14-Jul-2022    Application for quotation of securities - CPH  
 
14-Jul-2022    Creso Pharma ImpACTIVE appoints three new brand ambassadors  
 
12-Jul-2022    LOI secured with Providence Animal Health Korea Ltd  
 
11-Jul-2022    Notice of General Meeting/Proxy Form  
 
7-Jul-2022    HoA secured to launch SSH products in Singapore  
 
30-Jun-2022    Heads of Agreement secured to launch SSH products in Taiwan  
 
28-Jun-2022    Mernova Update  
 
15-Jun-2022    Application for quotation of securities - CPH  
 
15-Jun-2022    Application for quotation of securities - CPH  
 
15-Jun-2022    Notification of cessation of securities - CPH  
 
14-Jun-2022    Mernova Update  
 
31-May-2022    Amended Constitution  
 
31-May-2022    Results of Meeting  
 
30-May-2022    Halucenex Enters into Supply Agreement with Optimi Health  
 
23-May-2022    Creso Secures Heads of Agreement with Dr Pickles  
 
10-May-2022    Halucenex Secures Import Permit from Health Canada  
 
3-May-2022    Investor Presentation  
 
29-Apr-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
28-Apr-2022    Notice of Annual General Meeting/Proxy Form  
 
12-Apr-2022    ASX Listing Rule 3.13.1 Notice Regarding AGM  
 
7-Apr-2022    Sierra Sage Increases to 110,000 Points of Sale  
 
5-Apr-2022    US ROADSHOW - COMPANY PRESENTATION  
 
5-Apr-2022    Notification regarding unquoted securities - CPH  
 
5-Apr-2022    Application for quotation of securities - CPH  
 
4-Apr-2022    US House of Representatives Passes Cannabis Act  
 
1-Apr-2022    Proposed issue of securities - CPH  
 
1-Apr-2022    Notification of cessation of securities - CPH  
 
1-Apr-2022    LOI Secured with Laboratorios Brouwer for LATAM Market  
 
28-Mar-2022    Halucenex Update  
 
21-Mar-2022    Mernova reaches significant market share milestone  
 
16-Mar-2022    Sierra Sage to unlock US product sales and manufacturing  
 
4-Mar-2022    Secondary Trading Notice  
 
2-Mar-2022    Notification of cessation of securities - CPH  
 
2-Mar-2022    Application for quotation of securities - CPH  
 
28-Feb-2022    Appendix 4G and Corporate Governance Statement  
 
28-Feb-2022    Appendix 4E and Annual Report to Shareholders  
 
28-Feb-2022    Halucenex secures Clinical Trial Authorisation  
 
25-Feb-2022    Reinstatement to Official Quotation  
 
25-Feb-2022    Proposed issue of securities - CPH  
 
25-Feb-2022    Creso Pharma secures commitments to raise $5m  
 
24-Feb-2022    Suspension From Official Quotation  
 
22-Feb-2022    Trading Halt  
 
21-Feb-2022    Mernova Operational Update  
 
15-Feb-2022    Update on Acquisition of Sierra Sage Herbs  
 
11-Feb-2022    Creso Pharma to Develop New Hemp-Based Lozenge Product  
 
8-Feb-2022    Halucenex Update  
 
3-Feb-2022    Proposed issue of securities - CPH  
 
3-Feb-2022    Investor Presentation - Sierra Sage Acquisition  
 
3-Feb-2022    Creso to enter US CBD Market through Sierra Sage Acquisition  
 
31-Jan-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
28-Jan-2022    Application for quotation of securities - CPH  
 
28-Jan-2022    Application for quotation of securities - CPH  
 
25-Jan-2022    Halucenex Lodges Clinical Trial Authorisation  
 
24-Jan-2022    Initial Director's Interest Notice x3  
 
24-Jan-2022    Executive Director Remuneration  
 
17-Jan-2022    Proposed issue of securities - CPH  
 
17-Jan-2022    Creso Pharma Announces Three New Board Appointments  
 
11-Jan-2022    Halucenex Update  
 
6-Jan-2022    Release of Shares from Voluntary Escrow  
 
21-Dec-2021    Application for quotation of securities - CPH  
 
9-Dec-2021    Conversion of Performance Shares  
 
9-Dec-2021    Application for quotation of securities - CPH  
 
8-Dec-2021    Application for quotation of securities - CPH  
 
7-Dec-2021    Mernova on track for quarter-on-quarter revenue growth  
 
2-Dec-2021    Halucenex Awarded Dealer's License Amendment  
 
30-Nov-2021    Trading Halt  
 
25-Nov-2021    Update on Price and Volume Query Response  
 
23-Nov-2021    Trading Halt  
 
23-Nov-2021    Pause in Trading  
 
17-Nov-2021    Application for quotation of securities - CPH  
 
17-Nov-2021    Notification of cessation of securities - CPH  
 
16-Nov-2021    Response to ASX Price and Volume Query  
 
16-Nov-2021    Trading Halt  
 
16-Nov-2021    Pause in Trading  
 
15-Nov-2021    Creso Pharma Completes Integration of ImpACTIVE Assets  
 
11-Nov-2021    Creso Pharma Anticipates Increasing Q4 2021 Swiss Revenue  
 
9-Nov-2021    Dr Brian Walker Resigns as Strategic Consultant  
 
8-Nov-2021    Change of Director's Interest Notice x 3  
 
8-Nov-2021    Halucenex Receives Positive USP 61 and USP 62 Results  
 
5-Nov-2021    Notification regarding unquoted securities - CPH  
 
4-Nov-2021    Proposed issue of securities - CPH  
 
4-Nov-2021    Appointment of Hon. Dr Brian Walker as Strategic Advisor  
 
2-Nov-2021    Top 20 Holders  
 
2-Nov-2021    Distribution Schedule  
 
2-Nov-2021    Application for quotation of securities - CPH  
 
1-Nov-2021    Creso Pharma to Enter Swiss Medicinal Cannabis Market  
 
29-Oct-2021    Quarterly Activities/Appendix 4C Cash Flow Report  
 
27-Oct-2021    Application for quotation of securities - CPH  
 
26-Oct-2021    Secondary Trading Notice  
 
26-Oct-2021    Proposed issue of securities - CPH  
 
26-Oct-2021    Prospectus - Bonus Options  
 
25-Oct-2021    Creso Completes Acquisition of the Assets of ImpACTIVE  
 
25-Oct-2021    Notification regarding unquoted securities - CPH  
 
25-Oct-2021    Application for quotation of securities - CPH  
 
25-Oct-2021    Proposed issue of securities - CPH  
 
25-Oct-2021    Proposed issue of securities - CPH  
 
25-Oct-2021    Creso Pharma to Acquire ImpACTIVE Holdings Ltd Assets  
 
11-Oct-2021    Mernova Completes THC Content Testing on New Strains  
 
6-Oct-2021    Halucenex Update  
 
5-Oct-2021    Mernova Secures over A$800,000 in New Purchase Orders  
 
5-Oct-2021    Pause in Trading  
 
20-Sep-2021    Halucenex Secures Research Agreement with Acadia University  
 
20-Sep-2021    Pause in Trading  
 
17-Sep-2021    Creso Pharma Launches New E-commerce Channels  
 
13-Sep-2021    Secondary Trading Notice  
 
13-Sep-2021    Creso Secures New Purchase Orders for Human Health Products  
 
9-Sep-2021    Investor Presentation  
 
6-Sep-2021    Notification regarding unquoted securities - CPH  
 
6-Sep-2021    Proposed issue of securities - CPH  
 
6-Sep-2021    Application for quotation of securities - CPH  
 
6-Sep-2021    Creso Pharma Strengthens Management & Executive Team  
 
31-Aug-2021    Half Yearly Report and Accounts  
 
31-Aug-2021    Notification regarding unquoted securities - CPH  
 
31-Aug-2021    NASDAQ Listing & RLH Merger Update  
 
23-Aug-2021    Notification of cessation of securities - CPH  
 
23-Aug-2021    Halucenex Commissions Extraction Unit  
 
16-Aug-2021    Halucenex Awarded Dealer's License from Health Canada  
 
12-Aug-2021    Trading Halt  
 
12-Aug-2021    Pause in Trading  
 
11-Aug-2021    Mernova secures medicinal cannabis sales licence & new POs  
 
4-Aug-2021    Halucenex Continues to Make Progress ahead of Clinical Trial  
 
2-Aug-2021    Quarterly Update & Appendix 4C  
 
30-Jul-2021    Exercise of Options  
 
30-Jul-2021    Application for quotation of securities - CPH  
 
30-Jul-2021    Notification of cessation of securities - CPH  
 
30-Jul-2021    Mernova to Introduce Fourteen New Strains  
 
23-Jul-2021    Halucenex enters into a MOU with Landing Strong  
 
20-Jul-2021    Bruce Linton Confirms Position  
 
16-Jul-2021    CPH Launches cannaDOL through Multiple Distribution Channels  
 
15-Jul-2021    Change of Director's Interest Notice x 3  
 
15-Jul-2021    Creso Pharma Completes the Acquisition of Halucenex  
 
15-Jul-2021    Appendix 2A  
 
15-Jul-2021    Appendix 3G  
 
15-Jul-2021    Secondary Trading Notice  
 
13-Jul-2021    Notification of cessation of securities - CPH  
 
9-Jul-2021    Application for quotation of securities - CPH  
 
9-Jul-2021    Creso Completes Import Procedure in Uruguay for anibidiol  
 
7-Jul-2021    Change in substantial holding  
 
7-Jul-2021    Change of Director's Interest Notice  
 
6-Jul-2021    Creso Secures First Purchase Order from Red Light Holland  
 
2-Jul-2021    Halucenex Update  
 
1-Jul-2021    Reinstatement to Official Quotation  
 
1-Jul-2021    Creso's Second Consecutive Quarter of Record Revenue Growth  
 
29-Jun-2021    Suspension from Official Quotation  
 
25-Jun-2021    Trading Halt  
 
24-Jun-2021    Results of Meeting  
 
18-Jun-2021    Investor Presentation  
 
17-Jun-2021    Proposed issue of securities - CPH  
 
17-Jun-2021    Creso Pharma & Red Light Holland to Merge  
 
16-Jun-2021    Trading Halt  
 
11-Jun-2021    Creso Pharma completes US OTC dual listing  
 
8-Jun-2021    Halucenex Expands its Clinical Trials Plans  
 
4-Jun-2021    Distribution Agreement Expanded to Cover 14 Countries  
 
3-Jun-2021    Creso & Halucenex welcome Californian Senate Bill  
 
26-May-2021    Halucenex prepares North American market entry  
 
24-May-2021    Proposed issue of Securities - CPH  
 
24-May-2021    Update - Proposed issue of Securities - CPH  
 
24-May-2021    Update - Proposed issue of Securities - CPH  
 
24-May-2021    Update - Proposed issue of Securities - CPH  
 
21-May-2021    Notice of Annual General Meeting/Proxy Form  
 
21-May-2021    Creso Pharma signs Letter of Intent with Polvet  
 
18-May-2021    Creso Launches New Product  
 
17-May-2021    Mernova Awarded Craft Designation with OCS  
 
14-May-2021    Halucenex Secures Additional Pharmaceutical Grade Psilocybin  
 
12-May-2021    Trading Halt  
 
12-May-2021    Pause in Trading  
 
6-May-2021    Halucenex secures agreement with R&D partner Nucro-Technics  
 
5-May-2021    Appendix 2A  
 
30-Apr-2021    Quarterly Update & Appendix 4C  
 
19-Apr-2021    Halucenex Update  
 
14-Apr-2021    Commercial Agreement with Cannabis Queen, South Africa  
 
12-Apr-2021    ASX Listing Rule 3.13.1 Notice Regarding AGM  
 
12-Apr-2021    Halucenex Update  
 
8-Apr-2021    Mernova secures new purchase orders & launches new products  
 
6-Apr-2021    Creso appoints US executive to lead US entry strategy  
 
1-Apr-2021    Secondary Trading Notice  
 
1-Apr-2021    Appendix 2A  
 
1-Apr-2021    Creso launches three new CBD tea products  
 
31-Mar-2021    Creso continues positive progress with Halucenex  
 
29-Mar-2021    Proposed issue of Securities - CPH  
 
26-Mar-2021    Appendix 2A  
 
26-Mar-2021    Proposed issue of Securities - CPH  
 
26-Mar-2021    Creso Receives Firm Commitments to Raise $18M  
 
24-Mar-2021    Trading Halt  
 
23-Mar-2021    Creso to dual list on US OTC & Halucenex Update  
 
19-Mar-2021    Appendix 2A  
 
19-Mar-2021    New Mernova Purchase Orders & Launch of Pre-Roll Product  
 
17-Mar-2021    Final Director's Interest Notice  
 
17-Mar-2021    Halucenex Clinical Trial & Acquisition Update  
 
15-Mar-2021    Change of Director's Interest Notice  
 
15-Mar-2021    Halucenex Company Presentation  
 
15-Mar-2021    Proposed issue of Securities - CPH  
 
15-Mar-2021    Creso to Acquire Psychedelics Company, Halucenex  
 
9-Mar-2021    Appendix 4G & Corporate Governance Statement  
 
9-Mar-2021    Annual Report to shareholders  
 
9-Mar-2021    Creso Signs North American Sports Distribution Deal  
 
1-Mar-2021    Creso Signs With US Partner  
 
1-Mar-2021    Preliminary Final Report  
 
26-Feb-2021    Appendix 2A  
 
19-Feb-2021    Appendix 2A  
 
17-Feb-2021    New P.O.'s Demonstrate Strong Uptake  
 
15-Feb-2021    CPH enters Pakistan with $2.5m Distribution Deal  
 
12-Feb-2021    Appendix 2A  
 
8-Feb-2021    Creso brings cannaqix sales inhouse to improve margins  
 
5-Feb-2021    Secondary Trading Notice & Appendix 2A  
 
3-Feb-2021    New POs demonstrate patient uptake  
 
1-Feb-2021    CBD Oil legal in Australia - CPH to benefit  
 
29-Jan-2021    Quarterly Update and Appendix 4C  
 
27-Jan-2021    Change of Director's Interest Notice  
 
22-Jan-2021    Appendix 2A  
 
22-Jan-2021    Appendix 2A  
 
21-Jan-2021    Update - Proposed issue of Securities - CPH  
 
21-Jan-2021    Update - Proposed issue of Securities - CPH  
 
21-Jan-2021    Update - Proposed issue of Securities - CPH  
 
21-Jan-2021    Prospectus  
 
19-Jan-2021    Creso secures POs for record start to FY2021  
 
15-Jan-2021    Appendix 2A  
 
12-Jan-2021    CPH secures $320,000 revenue from second PO in South Africa  
 
11-Jan-2021    Appendix 2A  
 
11-Jan-2021    Becoming a substantial holder  
 
11-Jan-2021    Proposed issue of Securities - CPH  
 
8-Jan-2021    Creso readies for US cannabis legislation reform  
 
31-Dec-2020    Change of Director's Interest Notice  
 
24-Dec-2020    Creso to enter the Hash market in Canada  
 
23-Dec-2020    Appendix 2A  
 
23-Dec-2020    Results of Meeting  
 
21-Dec-2020    CPH Receives Regulatory Approval in Uruguay & Initial PO  
 
18-Dec-2020    Appendix 2A  
 
16-Dec-2020    CPH expands foot print in Canada & is now available online  
 
15-Dec-2020    Creso Welcomes TGA Decision to Reschedule CBD  
 
11-Dec-2020    Heads of Agreement to Unlock Australian Market  
 
9-Dec-2020    CPH Enters Canada's Largest Recreational Market  
 
7-Dec-2020    US House of Representatives Bill to Favour Creso in USA  
 
3-Dec-2020    Creso set to benefit from UN decision to reclassify cannabis  
 
2-Dec-2020    Creso Receives New Purchase Orders - EU  
 
30-Nov-2020    EU Ruling to Benefit Creso  
 
26-Nov-2020    Proposed issue of Securities - CPH  
 
26-Nov-2020    TGA Update  
 
23-Nov-2020    Notice of General Meeting/Proxy Form  
 
30-Oct-2020    Quarterly Update and Appendix 4C  
 
27-Oct-2020    Third Purchase Order from Nova Scotia Liquor Corporation  
 
14-Oct-2020    Ceasing to be a substantial holder  
 
14-Oct-2020    Israeli Market Update  
 
13-Oct-2020    Ceasing to be a substantial holder  
 
13-Oct-2020    Cleansing Prospectus  
 
12-Oct-2020    Secured Debt Update  
 
12-Oct-2020    Change of Director's Interest Notice x 2  
 
12-Oct-2020    Appendix 2A  
 
12-Oct-2020    Change in substantial holding  
 
12-Oct-2020    Second Purchase Order from Pharma Dynamics, South Africa  
 
9-Oct-2020    Second Retail PO from Nova Scotia Liquor Corporation  
 
7-Oct-2020    Canopy Growth founder to join Creso  
 
7-Oct-2020    Proposed issue of Securities - CPH  
 
7-Oct-2020    Proposed issue of Securities - CPH  
 
7-Oct-2020    Creso Pharma receives commitments totaling A$8.992m  
 
6-Oct-2020    Becoming a substantial holder  
 
6-Oct-2020    Ceasing to be a substantial holder  
 
5-Oct-2020    Appendix 2A  
 
2-Oct-2020    Results of Meeting  
 
1-Oct-2020    Trading Halt  
 
30-Sep-2020    Appendix 2A  
 
22-Sep-2020    Addendum to Notice of General Meeting  
 
21-Sep-2020    Mernova Receives First Retail Purchase Order From NSLC  
 
10-Sep-2020    Creso welcomes TGA reclassification of CBD  
 
1-Sep-2020    Appendix 2A  
 
1-Sep-2020    Half Yearly Report and Accounts  
 
28-Aug-2020    Proposed issue of Securities - CPH  
 
27-Aug-2020    Notice of General Meeting/Proxy Form  
 
14-Aug-2020    Company Update  
 
12-Aug-2020    Agreement with DHS Business for Entry into Iberic Markets  
 
3-Aug-2020    Appendix 2A  
 
3-Aug-2020    Quarterly Activities Report and Appendix 4C  
 
15-Jul-2020    Ceasing to be a substantial holder  
 
10-Jul-2020    Mernova Receives US$625k Order for Shipment to Israel  
 
3-Jul-2020    Redemption of Performance Shares  
 
1-Jul-2020    Ceasing to be a substantial holder  
 
30-Jun-2020    Ceasing to be a substantial holder  
 
26-Jun-2020    Appendix 2A  
 
26-Jun-2020    Becoming a substantial holder  
 
26-Jun-2020    Proposed issue of Securities - CPH  
 
26-Jun-2020    Mernova Milestone 2 Update  
 
25-Jun-2020    Issue of Unlisted Securities  
 
25-Jun-2020    Prospectus Offer Period Extension  
 
25-Jun-2020    Appendix 2A  
 
24-Jun-2020    Prospectus Offer Period Extension  
 
24-Jun-2020    Appendix 2A  
 
24-Jun-2020    Mernova Operational Update  
 
24-Jun-2020    Cleansing Prospectus  
 
23-Jun-2020    Appendix 2A  
 
23-Jun-2020    Proposed issue of Securities - CPH  
 
16-Jun-2020    Results of Meeting  
 
15-Jun-2020    Ceasing to be a substantial holder  
 
11-Jun-2020    Change in substantial holding  
 
11-Jun-2020    Israeli Cannabis Legislation Update  
 
10-Jun-2020    Update on Mernova Sales License  
 
9-Jun-2020    Change of Director's Interest Notice  
 
9-Jun-2020    Becoming a substantial holder  
 
9-Jun-2020    Successful launch of Creso's Cannamics in South Africa  
 
4-Jun-2020    Appendix 2A  
 
3-Jun-2020    Appendix 2A  
 
3-Jun-2020    Agreement for Entry into Brazilian Retail Market  
 
2-Jun-2020    Proposed issue of Securities - CPH  
 
2-Jun-2020    Cleansing Prospectus  
 
2-Jun-2020    Placement and Corporate Update  
 
2-Jun-2020    Appendix 2A  
 
1-Jun-2020    Creso Pharma Receives Firm Commitments to Raise A$2.137M  
 
1-Jun-2020    Appendix 2A  
 
1-Jun-2020    Proposed issue of Securities - CPH  
 
28-May-2020    Appendix 2A  
 
28-May-2020    Proposed issue of Securities - CPH  
 
28-May-2020    Appendix 2A  
 
27-May-2020    Trading Halt  
 
18-May-2020    Results of Meeting  
 
13-May-2020    Update on Mernova Sales Licence  
 
12-May-2020    Letter to Shareholders Regarding AGM  
 
12-May-2020    Notice of Annual General Meeting/Proxy Form  
 
11-May-2020    Trading Halt  
 
11-May-2020    Pause In Trade  
 
11-May-2020    Mernova Receives Retail Sales License from Health Canada  
 
30-Apr-2020    Quarterly Update and Appendix 4C (Replacement)  
 
30-Apr-2020    Quarterly Update and Appendix 4C  
 
20-Apr-2020    Appendix 2A  
 
20-Apr-2020    Cleansing Prospectus  
 
20-Apr-2020    Proposed issue of Securities - CPH  
 
20-Apr-2020    Proposed issue of Securities - CPH  
 
20-Apr-2020    Proposed issue of Securities - CPH  
 
20-Apr-2020    Proposed issue of Securities - CPH  
 
20-Apr-2020    Funding Update  
 
20-Apr-2020    Israeli JV Update  
 
15-Apr-2020    Notice of General Meeting/Proxy Form  
 
14-Apr-2020    L1 Capital Collateral Purchase Notice & Top-Up Notice  
 
14-Apr-2020    Pause in Trading  
 
14-Apr-2020    Binding LOI to Expand Distribution into Pakistan  
 
8-Apr-2020    ASX Listing Rule 3.13.1 Notice Regarding AGM  
 
7-Apr-2020    Appendix 3G  
 
7-Apr-2020    Creso Completes AUD 200,000 Order of anibidiol to Virbac  
 
2-Apr-2020    Creso Pharma Outlines Response to COVID-19  
 
2-Apr-2020    Pause in Trading  
 
1-Apr-2020    Mernova Receives C$775k Order for First Shipment to Israel  
 
26-Mar-2020    First Shipment of cannaQIX to South Africa For Launch in Q2  
 
24-Mar-2020    Creso Pharma to Launch CBD Hemp Tea  
 
12-Mar-2020    Ceasing to be a substantial holder - Correction  
 
11-Mar-2020    Ceasing to be a substantial holder  
 
11-Mar-2020    Creso Strengthens Mernova Senior Management Team  
 
10-Mar-2020    Trading Halt  
 
10-Mar-2020    Pause in Trading  
 
6-Mar-2020    Becoming a substantial holder  
 
3-Mar-2020    Creso Signs Agreement to Market its Products in Scandinavia  
 
2-Mar-2020    Termination of Israeli Joint Venture  
 
28-Feb-2020    Appendix 4G & Corporate Governance Statement  
 
28-Feb-2020    Preliminary Report & Annual Report to shareholders  
 
19-Feb-2020    Change of Director's Interest Notice  
 
18-Feb-2020    Appendix 2A  
 
18-Feb-2020    Change in substantial holding  
 
14-Feb-2020    Mernova Milestone 2 Achieved  
 
12-Feb-2020    Issue of Unquoted Securities  
 
11-Feb-2020    Proposed issue of Securities - CPH  
 
11-Feb-2020    Appendix 2A  
 
11-Feb-2020    Appendix 2A  
 
11-Feb-2020    Creso to launch hemp product for equines and large animals  
 
11-Feb-2020    Supplementary Prospectus  
 
7-Feb-2020    Prospectus  
 
6-Feb-2020    Technological Breakthrough for Human Health Products  
 
5-Feb-2020    Appendix 2A  
 
5-Feb-2020    Proposed issue of Securities - CPH  
 
5-Feb-2020    Creso Pharma Secures Further Funding  
 
30-Jan-2020    New Constitution  
 
28-Jan-2020    Results of Meeting  
 
28-Jan-2020    Creso exceeds milestone of 2.5m cannaQIX lozenges sold  
 
23-Jan-2020    Change in substantial holding  
 
21-Jan-2020    Re-engagement of Corporate Advisor  
 
21-Jan-2020    Creso exceeds milestone of 3m anibidiol doses sold in Europe  
 
17-Jan-2020    Quarterly Update and Appendix 4C  
 
13-Jan-2020    Addendum to Notice of General Meeting  
 
8-Jan-2020    Release of Securities From Voluntary Escrow  
 
8-Jan-2020    Response to ASX Price Query  
 
31-Dec-2019    Convertible Note Facility Drawdown  
 
23-Dec-2019    Notice of General Meeting/Proxy Form  
 
19-Dec-2019    Change in substantial holding  
 
12-Dec-2019    Release of Securities From Voluntary Escrow  
 
9-Dec-2019    Creso enters the African continent with cannaQIX products  
 
5-Dec-2019    Commencement of sales of cannaQIX 50 in Australia with BHC  
 
3-Dec-2019    Corporate Presentation - December 2019  
 
2-Dec-2019    Appendix 3B  
 
2-Dec-2019    Placement under ASX Listing Rule 7.1A  
 
2-Dec-2019    Appendix 3B  
 
2-Dec-2019    Reinstatement to Official Quotation  
 
2-Dec-2019    Update on Strategy and Plans to Accelerate Global Operations  
 
28-Nov-2019    Appendix 3B  
 
28-Nov-2019    Waiver from ASX Listing Rule 10.1  
 
28-Nov-2019    Disclosure Document - Debt Note Offer & Cleansing Offer  
 
12-Nov-2019    Termination of Scheme Implementation Agreement  
 
11-Nov-2019    Adjournment of Scheme Meetings  
 
8-Nov-2019    Update on Voluntary Suspension  
 
5-Nov-2019    Suspension from Official Quotation  
 
1-Nov-2019    Trading Halt  
 
1-Nov-2019    Pause in Trade  
 
17-Oct-2019    First Shipment of 10% Medicinal CBD Oil in New Zealand  
 
14-Oct-2019    Quarterly Update & Appendix 4C  
 
4-Oct-2019    Scheme Booklet (Replacement)  
 
4-Oct-2019    Scheme Booklet  
 
4-Oct-2019    Reinstatement to Official Quotation  
 
3-Oct-2019    Update on Proposed Acquisition by PharmaCielo  
 
27-Sep-2019    Update on Proposed Acquisition by PharmaCielo  
 
18-Sep-2019    Voluntary Suspension  
 
16-Sep-2019    Trading Halt  
 
16-Sep-2019    Pause in Trading  
 
16-Sep-2019    Creso Granted Processing Licence for its Mernova Facility  
 
4-Sep-2019    Release of Securities From Voluntary Escrow  
 
26-Aug-2019    Half Yearly Report and Accounts  
 
22-Aug-2019    Creso Signs with Pharma Dynamics for cQIX in South Africa  
 
20-Aug-2019    Creso Receives PCLO's First Commercial CBD Export into EU  
 
8-Aug-2019    Additional Information on Medleaf Distribution Agreement  
 
6-Aug-2019    Distribution Agreement with Medleaf NZ for CBD Products  
 
2-Aug-2019    Change of Director's Interest Notice  
 
1-Aug-2019    First Order of cannaQIX50 from Burleigh Heads Cannabis  
 
31-Jul-2019    Cleansing Statement and Appendix 3B  
 
24-Jul-2019    Quarterly Update & Appendix 4C  
 
15-Jul-2019    Change in substantial holding  
 
15-Jul-2019    Change in substantial holding  
 
12-Jul-2019    Cleansing Statement and Appendix 3B  
 
10-Jul-2019    Becoming a substantial holder  
 
8-Jul-2019    Appendix 3Y x 4  
 
3-Jul-2019    Creso Repays Debt in Preparation for Acquisition & App 3B  
 
2-Jul-2019    Creso Begins Revenue Generation from Canadian Cannabis Sales  
 
7-Jun-2019    Creso Pharma To Be Acquired  
 
4-Jun-2019    Release of Securities From Voluntary Escrow  
 
31-May-2019    Results of Meeting  
 
23-May-2019    Creso Harvests First Cannabis Crop in Canada  
 
30-Apr-2019    BHC Distribution Agreement & Australian Import Permit  
 
29-Apr-2019    Quarterly Update & Appendix 4C  
 
29-Apr-2019    Notice of Annual General Meeting/Proxy Form  
 
23-Apr-2019    Brazil Import Licence - Additional Information  
 
18-Apr-2019    Brazil Import Licence Granted For cannaQIX  
 
15-Apr-2019    Creso Pharma Canadian Cultivation Update  
 
11-Apr-2019    Additional Information on Secured Loans  
 
11-Apr-2019    Creso to Raise AUD5.35m via Secured Loans  
 
9-Apr-2019    Trading Halt  
 
5-Apr-2019    Response to ASX Aware Query  
 
2-Apr-2019    Commercial Progress Across Premium Product Categories  
 
27-Mar-2019    Appendix 4G & Corporate Governance Statement  
 
25-Mar-2019    Annual Report to shareholders  
 
6-Mar-2019    Release of Securities From Voluntary Escrow  
 
28-Feb-2019    CEO's Report on Operations & Appendix 4E  
 
18-Feb-2019    Creso Granted License to Cultivate Cannabis  
 
14-Feb-2019    Strategic Collaboration for CBD products with Hempmate Switz  
 
13-Feb-2019    Strategic Collaboration with Burleigh Heads Cannabis  
 
12-Feb-2019    Reinstatement to Official Quotation  
 
12-Feb-2019    Clarification and Reinstatement to Trading  
 
6-Feb-2019    Suspension Update  
 
4-Feb-2019    Suspension from Official Quotation  
 
1-Feb-2019    Cleansing Statement & Appendix 3B  
 
1-Feb-2019    Trading Halt  
 
1-Feb-2019    Pause In Trading  
 
1-Feb-2019    Colombian Partnership and Appointment of Medical Advisor  
 
31-Jan-2019    Quarterly Update & Appendix 4C  
 
31-Jan-2019    Placement Update, Cleansing Statement & Appendix 3B  
 
30-Jan-2019    Creso and CLV Expand the OBMJ Beers to Switzerland  
 
24-Jan-2019    Creso Raises $3 Million in Institutional Placement  
 
22-Jan-2019    Trading Halt  
 
21-Jan-2019    Creso Signs Supply Agreement with TerrAscend Canada  
 
9-Jan-2019    Creso further builds medical cannabis in NZ with Medleaf  
 
7-Jan-2019    Strategic Collaboration in Sri Lanka for Medical Cannabis  
 
2-Jan-2019    Creso builds on Israel's new Med Cannabis export law